BloodSpot data indicated that the highest expression of BIRC5 was in AML patients with complex cytogenetic abnormalities compared (Figure 2B) with all other cytogenetic abnormalities while MILE data indicated a correlation between higher levels of BIRC5 and poor prognosis cytogenetics (p = 0.02). Here, BIRC5 is linked to acute myeloid leukemia.